Overview

Metastatic Nasopharyngeal Carcinoma

Status:
RECRUITING

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.

Phase:

PHASE1

Details

Lead Sponsor:

Chen Xiaozhong

Treatments:

Gemcitabine